SiBone $SIBN Shares Sold by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC reduced its stake in shares of SiBone (NASDAQ:SIBN) by 42.2% during the third quarter, Holdings Channel.com reports. The firm owned 59,254 shares of the company’s stock after selling 43,291 shares during the period. Lisanti Capital Growth LLC’s holdings in SiBone were worth $872,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SIBN. State of Alaska Department of Revenue acquired a new position in SiBone during the 3rd quarter valued at about $39,000. State of Wyoming bought a new position in shares of SiBone in the second quarter valued at approximately $55,000. Canada Pension Plan Investment Board acquired a new position in shares of SiBone during the second quarter valued at approximately $68,000. Tower Research Capital LLC TRC increased its stake in shares of SiBone by 198.8% during the second quarter. Tower Research Capital LLC TRC now owns 4,897 shares of the company’s stock valued at $92,000 after acquiring an additional 3,258 shares during the period. Finally, State of Tennessee Department of Treasury bought a new stake in SiBone during the second quarter worth approximately $137,000. Institutional investors own 98.11% of the company’s stock.

SiBone Trading Up 0.2%

Shares of SIBN opened at $16.58 on Friday. The business’s 50-day moving average price is $18.94 and its 200 day moving average price is $17.01. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $719.41 million, a P/E ratio of -32.51 and a beta of 0.69. SiBone has a 1-year low of $12.49 and a 1-year high of $21.89.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. The company had revenue of $48.66 million during the quarter, compared to analyst estimates of $46.67 million. Analysts expect that SiBone will post -0.78 earnings per share for the current year.

Insiders Place Their Bets

In other SiBone news, CFO Anshul Maheshwari sold 5,229 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $19.64, for a total transaction of $102,697.56. Following the sale, the chief financial officer directly owned 180,002 shares of the company’s stock, valued at $3,535,239.28. The trade was a 2.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anthony J. Recupero sold 3,677 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $19.62, for a total value of $72,142.74. Following the completion of the sale, the insider owned 264,467 shares of the company’s stock, valued at $5,188,842.54. The trade was a 1.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 207,886 shares of company stock worth $3,996,367 in the last quarter. Corporate insiders own 4.00% of the company’s stock.

Wall Street Analysts Forecast Growth

SIBN has been the subject of a number of research reports. Canaccord Genuity Group increased their price target on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Truist Financial boosted their price objective on SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. TD Cowen raised SiBone to a “strong-buy” rating in a research note on Tuesday. Needham & Company LLC lifted their target price on SiBone from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Morgan Stanley upped their price target on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.33.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.